title: [A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
abstract: A 57-year-old multiparous woman with FIGO stage IV ovarian cancer underwent primary surgery and was administered postoperative chemotherapy consisting of paclitaxel and carboplatin (TC). Complete response was confirmed on computed tomography. After a 20-month platinum free interval (PFI), an elevated serum CA125 level and recurrence in the peritoneum were confirmed, and she was retreated with TC as second-line chemotherapy. A hypersensitivity reaction occurred after administering the second dose of carboplatin; therefore, carboplatin was changed to nedaplatin. Complete response was confirmed on computed tomography, and the serum CA125 level returned to normal. After an 8-month PFI, an elevated serum CA125 level and recurrence in the peritoneum and liver were confirmed, and she was treated with 6 cycles of combination chemotherapy consisting of gemcitabine (1,000 mg/m2: day 1 and 8 q3 weeks)and nedaplatin (80 mg/m2: day 1 q3 weeks). Only cytopenia (grade 2: CTCAE v4.0) was noted as a complication during chemotherapy. Complete response was confirmed on computed tomography. This report presents the case of a patient with recurrent ovarian cancer who was platinum sensitive and successfully treated with gemcitabine and nedaplatin after showing a hypersensitivity reaction to carboplatin.
authors.affiliation: Dept. of Obstetrics and Gynecology, NTT Medical Center Tokyo.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Asami
authors.forename: Ryo
authors.initials: R
authors.lastname: Kitagawa
authors.forename: Moe
authors.initials: M
authors.lastname: Iiba
authors.forename: Asami
authors.initials: A
authors.lastname: Uenoyama
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kondo
authors.forename: Nakako
authors.initials: N
authors.lastname: Sato
authors.forename: Kaoru
authors.initials: K
authors.lastname: Tadauchi
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Sugita
authors.forename: Hajime
authors.initials: H
authors.lastname: Tsunoda
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D003841:Deoxycytidine; C053989:nedaplatin; D016190:Carboplatin; D000093542:Gemcitabine